 Theratechnologies Inc NASDAQ: THTX has announced new preclinical in vivo findings on its peptide-drug conjugate PDC, TH1902. The results demonstrate that TH1902 has better anti-metastatic activity when compared to docetaxel alone when administered at an equimolar concentration in a lung metastasis cancer model expressing the sortilin SORT1 receptor. 